OPT-ISM Weekly Quiz: Clinical Myopia Control

Opt-ism Eye Care weekly quiz poster with moon rocket graphic and text: Test your knowledge, Learn, Focus, Grow

Question 1: A 10-year-old child undergoing myopia-control treatment demonstrates 0.22 mm of axial elongation over 12 months. What is the most appropriate interpretation?

A. This confirms treatment failure

B. This represents excellent control in all children

C. This should raise concern for continued progression and prompt reassessment

D. Axial length is not useful once treatment has started

Question 2: Which measurement is especially useful for objectively monitoring the structural progression of childhood myopia?

A. Near visual acuity

B. Axial length

C. Pupillary distance

D. Corneal diameter

Question 3: A child using MiSight lenses reports wearing them approximately 4 hours per day, 3 days per week. Axial length continues to increase. What should the clinician evaluate first?

A. Immediately discontinue MiSight

B. Add atropine without further evaluation

C. Improve and verify treatment compliance and wearing time

D. Assume the child is a biological nonresponder

Question 4: Among commonly used low-dose atropine concentrations, which demonstrated the greatest myopia-control efficacy in the LAMP studies?

A. 0.005%

B. 0.01%

C. 0.025%

D. 0.05%

Question 5: A child wearing orthokeratology lenses has excellent unaided daytime vision and a well-centered treatment zone. Why should axial length still be monitored?

A. Ortho-K permanently shortens the eye

B. Good daytime vision does not necessarily mean axial elongation has stopped

C. Axial length determines whether the lens is centered

D. Topography cannot evaluate corneal reshaping

Question 6: Which combination therapy currently has some of the strongest clinical evidence for providing additional myopia-control benefit compared with monotherapy?

A. Single-vision spectacles + atropine

B. MiSight + single-vision spectacles

C. Orthokeratology + low-dose atropine

D. Ortho-K + undercorrected spectacles

Answer Key

1. C — This should raise concern for continued progression and prompt reassessment.

Axial elongation around or above 0.20 mm per year is a useful clinical warning sign for ongoing progression, especially in older children. It does not automatically prove treatment failure, but it should prompt the clinician to review age, previous growth rate, refraction, compliance, and treatment effectiveness.

2. B — Axial length.

Axial length provides an objective measurement of ocular growth and is one of the most useful tools for following pediatric myopia over time. Refraction remains important, but axial length can reveal continued eye growth even when the prescription appears relatively stable.

3. C — Improve and verify treatment compliance and wearing time.

Before labeling a treatment as ineffective, confirm that the child is receiving adequate treatment exposure. Poor MiSight wear time can mimic treatment failure. The clinician should first review hours per day, days per week, comfort, handling, and whether the child is frequently substituting glasses.

4. D — 0.05%.

The LAMP studies demonstrated a concentration-dependent atropine effect, with 0.05% atropine producing greater control of both refractive progression and axial elongation than 0.025% or 0.01%. Concentration selection should still balance efficacy, age, progression risk, and side effects such as photophobia or near blur.

5. B — Good daytime vision does not necessarily mean axial elongation has stopped.

Orthokeratology can provide excellent unaided vision by reshaping the cornea, but that does not guarantee that the eye itself has stopped elongating. Topography tells the clinician how well the cornea is being reshaped, while axial length helps determine whether the underlying myopia is still progressing.

6. C — Orthokeratology + low-dose atropine.

Combination therapy with ortho-K plus low-dose atropine has some of the strongest evidence for an additive myopia-control effect. It may be considered when a child has a good ortho-K fit and good compliance but continues to demonstrate excessive axial elongation.

Score Guide:

6/6: Excellent — strong clinical understanding of myopia management.

4–5/6: Very good — review treatment-failure criteria and escalation strategies.

2–3/6: Keep reviewing axial-length interpretation and treatment selection.

0–1/6: Revisit the clinical myopia-control decision tree before managing the next progressor.